Austin-Zimmerman I, Spinazzola E, Quattrone D, Wu-Choi B, Trotta G, Li Z
Psychol Med. 2024; :1-13.
PMID: 39637925
PMC: 11650186.
DOI: 10.1017/S0033291724002058.
Osborne K, Barch D, Jackson J, Karcher N
JAMA Psychiatry. 2024; 82(2):181-190.
PMID: 39504015
PMC: 11541740.
DOI: 10.1001/jamapsychiatry.2024.3525.
Martinez M, Vera V, Ruiz C, Floresco S, Mahler S
Psychopharmacology (Berl). 2024; 242(2):309-326.
PMID: 39190156
DOI: 10.1007/s00213-024-06676-9.
Martinez M, Vera V, Ruiz C, Floresco S, Mahler S
bioRxiv. 2024; .
PMID: 38826339
PMC: 11142049.
DOI: 10.1101/2024.04.12.588937.
Shafiee A, Rafiei M, Jafarabady K, Eskandari A, Abhari F, Sattari M
Brain Behav. 2024; 14(1):e3340.
PMID: 38376038
PMC: 10757895.
DOI: 10.1002/brb3.3340.
Aberrant salience in cannabis-induced psychosis: a comparative study.
Ricci V, Di Muzio I, Ceci F, Di Carlo F, Mancusi G, Piro T
Front Psychiatry. 2024; 14:1343884.
PMID: 38260781
PMC: 10801803.
DOI: 10.3389/fpsyt.2023.1343884.
Remission with or without comorbid substance use disorders in early psychosis: long-term outcome in integrated care (ACCESS III study).
Ruhl F, Lambert M, Rohenkohl A, Kraft V, Daubmann A, Schneider B
Front Psychol. 2024; 14:1237718.
PMID: 38187418
PMC: 10768197.
DOI: 10.3389/fpsyg.2023.1237718.
Rewiring the future: drugs abused in adolescence may predispose to mental illness in adult life by altering dopamine axon growth.
Avramescu R, Hernandez G, Flores C
J Neural Transm (Vienna). 2023; 131(5):461-467.
PMID: 38036858
PMC: 11055695.
DOI: 10.1007/s00702-023-02722-6.
Neurotrophic Factors in Cannabis-induced Psychosis: An Update.
Ricci V, de Berardis D, Martinotti G, Maina G
Curr Top Med Chem. 2023; 24(20):1757-1772.
PMID: 37644743
DOI: 10.2174/1568026623666230829152150.
Recreational Marijuana Use, Adolescent Cognitive Development, and Schizophrenia Susceptibility.
Ho B, Barry A, Koeppel J, Macleod J, Boyd A, David A
Biol Psychiatry Glob Open Sci. 2023; 3(2):222-232.
PMID: 37124347
PMC: 10140454.
DOI: 10.1016/j.bpsgos.2022.01.008.
Epigenomic and Other Evidence for Cannabis-Induced Aging Contextualized in a Synthetic Epidemiologic Overview of Cannabinoid-Related Teratogenesis and Cannabinoid-Related Carcinogenesis.
Reece A, Hulse G
Int J Environ Res Public Health. 2022; 19(24).
PMID: 36554603
PMC: 9778714.
DOI: 10.3390/ijerph192416721.
Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.
Ricci V, Martinotti G, de Berardis D, Maina G
Int J Environ Res Public Health. 2022; 19(23).
PMID: 36498129
PMC: 9737174.
DOI: 10.3390/ijerph192316057.
Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients.
Ibarra-Lecue I, Unzueta-Larrinaga P, Barrena-Barbadillo R, Villate A, Horrillo I, Mendivil B
Addict Biol. 2022; 27(6):e13233.
PMID: 36301212
PMC: 9539611.
DOI: 10.1111/adb.13233.
Noninvasive Brain Stimulation for Nicotine Dependence in Schizophrenia: A Mini Review.
Ward H, Brady R, Halko M, Lizano P
Front Psychiatry. 2022; 13:824878.
PMID: 35222123
PMC: 8863675.
DOI: 10.3389/fpsyt.2022.824878.
Gene-Environment Interactions in Schizophrenia: A Literature Review.
Wahbeh M, Avramopoulos D
Genes (Basel). 2021; 12(12).
PMID: 34946799
PMC: 8702084.
DOI: 10.3390/genes12121850.
Association of Cannabis Use-Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001-2002 and 2012-2013.
Livne O, Shmulewitz D, Sarvet A, Wall M, Hasin D
Am J Psychiatry. 2021; 179(1):36-45.
PMID: 34645275
PMC: 8945254.
DOI: 10.1176/appi.ajp.2021.21010073.
The Impact of THC and CBD in Schizophrenia: A Systematic Review.
Ahmed S, Roth R, Stanciu C, Brunette M
Front Psychiatry. 2021; 12:694394.
PMID: 34366924
PMC: 8343183.
DOI: 10.3389/fpsyt.2021.694394.
Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.
Breijyeh Z, Jubeh B, Bufo S, Karaman R, Scrano L
Toxins (Basel). 2021; 13(2).
PMID: 33562446
PMC: 7915118.
DOI: 10.3390/toxins13020117.
Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis.
Theunissen E, Reckweg J, Hutten N, Kuypers K, Toennes S, Neukamm M
Psychopharmacology (Berl). 2021; 239(5):1251-1261.
PMID: 33501595
PMC: 9110546.
DOI: 10.1007/s00213-021-05768-0.
Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review.
Hasin D, Walsh C
J Clin Med. 2020; 10(1).
PMID: 33374666
PMC: 7793504.
DOI: 10.3390/jcm10010015.